Literature DB >> 29859301

Presence of multiple Clostridium difficile strains at primary infection is associated with development of recurrent disease.

Anna M Seekatz1, Emily Wolfrum2, Christopher M DeWald3, Rosemary K B Putler1, Kimberly C Vendrov1, Krishna Rao1, Vincent B Young4.   

Abstract

Recurrence of Clostridium difficile infection (CDI) places a major burden on the healthcare system. Previous studies have suggested that specific C. difficile strains, or ribotypes, are associated with severe disease and/or recurrence. However, in some patients a new strain is detected in subsequent infections, complicating longitudinal studies focused on strain differences that may contribute to disease outcome. We examined ribotype composition over time in patients who did or did not develop recurrence to examine infection with multiple C. difficile ribotypes (mixed infection), during the course of infection. Using a retrospective patient cohort, we isolated and ribotyped a median of 36 C. difficile colonies from 61 patients (105 total samples) at initial infection, recurrence (a second case of CDI within 15-56 days of initial infection), and reinfection (a second case of CDI after 56 days of initial infection). We observed mixed infection in 78.6% of samples at initial infection in patients who went on to develop recurrence compared to 18.1% of patients who did not, and mixed infection remained associated with subsequent recurrence after adjusting for gender and prior antibiotic exposure (OR 3.5, 95% CI 1.3-9.4, P = .015). In patients who were sampled longitudinally (44 consecutive events in 32 patients), the dominant ribotype changed in 31.8% of consecutive samples and the newly dominant ribotype was not detected in prior samples from that patient. Our results suggest that mixed C. difficile infection is more prevalent than previously demonstrated and potentially a marker of susceptibility to recurrence.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  C. difficile ribotypes; Clostridium difficile infection; Recurrent infection

Mesh:

Year:  2018        PMID: 29859301      PMCID: PMC6274632          DOI: 10.1016/j.anaerobe.2018.05.017

Source DB:  PubMed          Journal:  Anaerobe        ISSN: 1075-9964            Impact factor:   3.331


  30 in total

1.  Clostridium difficile mixed infection and reinfection.

Authors:  David W Eyre; A Sarah Walker; David Griffiths; Mark H Wilcox; David H Wyllie; Kate E Dingle; Derrick W Crook; Tim E A Peto
Journal:  J Clin Microbiol       Date:  2011-11-09       Impact factor: 5.948

2.  Relapse versus reinfection: surveillance of Clostridium difficile infection.

Authors:  Mini Kamboj; Perminder Khosa; Anna Kaltsas; N Esther Babady; Crystal Son; Kent A Sepkowitz
Journal:  Clin Infect Dis       Date:  2011-10-05       Impact factor: 9.079

3.  An epidemic, toxin gene-variant strain of Clostridium difficile.

Authors:  L Clifford McDonald; George E Killgore; Angela Thompson; Robert C Owens; Sophia V Kazakova; Susan P Sambol; Stuart Johnson; Dale N Gerding
Journal:  N Engl J Med       Date:  2005-12-01       Impact factor: 91.245

4.  Molecular and microbiological characterization of Clostridium difficile isolates from single, relapse, and reinfection cases.

Authors:  Kentaro Oka; Takako Osaki; Tomoko Hanawa; Satoshi Kurata; Mitsuhiro Okazaki; Taki Manzoku; Motomichi Takahashi; Mamoru Tanaka; Haruhiko Taguchi; Takashi Watanabe; Takashi Inamatsu; Shigeru Kamiya
Journal:  J Clin Microbiol       Date:  2012-01-11       Impact factor: 5.948

5.  Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea.

Authors:  L Kyne; M Warny; A Qamar; C P Kelly
Journal:  Lancet       Date:  2001-01-20       Impact factor: 79.321

6.  Coexistence of multiple PCR-ribotype strains of Clostridium difficile in faecal samples limits epidemiological studies.

Authors:  Renate J van den Berg; Hadi Aa Ameen; Takahiro Furusawa; Eric Cj Claas; Eric R van der Vorm; Ed J Kuijper
Journal:  J Med Microbiol       Date:  2005-02       Impact factor: 2.472

7.  Recommendations for surveillance of Clostridium difficile-associated disease.

Authors:  L Clifford McDonald; Bruno Coignard; Erik Dubberke; Xiaoyan Song; Teresa Horan; Preeta K Kutty
Journal:  Infect Control Hosp Epidemiol       Date:  2007-01-25       Impact factor: 3.254

8.  Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA).

Authors:  Stuart H Cohen; Dale N Gerding; Stuart Johnson; Ciaran P Kelly; Vivian G Loo; L Clifford McDonald; Jacques Pepin; Mark H Wilcox
Journal:  Infect Control Hosp Epidemiol       Date:  2010-05       Impact factor: 3.254

9.  Rapid molecular characterization of Clostridium difficile and assessment of populations of C. difficile in stool specimens.

Authors:  Danielle Wroblewski; George E Hannett; Dianna J Bopp; Ghinwa K Dumyati; Tanya A Halse; Nellie B Dumas; Kimberlee A Musser
Journal:  J Clin Microbiol       Date:  2009-04-29       Impact factor: 5.948

Review 10.  Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes.

Authors:  Stuart Johnson
Journal:  J Infect       Date:  2009-04-05       Impact factor: 6.072

View more
  9 in total

1.  Clostridioides difficile Whole-Genome Sequencing Reveals Limited Within-Host Genetic Diversity in a Pediatric Cohort.

Authors:  Aakash Balaji; Egon A Ozer; Larry K Kociolek
Journal:  J Clin Microbiol       Date:  2019-08-26       Impact factor: 5.948

Review 2.  Capturing the environment of the Clostridioides difficile infection cycle.

Authors:  Matthew K Schnizlein; Vincent B Young
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-04-25       Impact factor: 73.082

3.  Integrated Meta-omics Reveals a Fungus-Associated Bacteriome and Distinct Functional Pathways in Clostridioides difficile Infection.

Authors:  David B Stewart; Justin R Wright; Maria Fowler; Christopher J McLimans; Vasily Tokarev; Isabella Amaniera; Owen Baker; Hoi-Tong Wong; Jeff Brabec; Rebecca Drucker; Regina Lamendella
Journal:  mSphere       Date:  2019-08-28       Impact factor: 4.389

4.  Protection from Lethal Clostridioides difficile Infection via Intraspecies Competition for Cogerminant.

Authors:  Jhansi L Leslie; Matthew L Jenior; Kimberly C Vendrov; Alexandra K Standke; Madeline R Barron; Tricia J O'Brien; Lavinia Unverdorben; Pariyamon Thaprawat; Ingrid L Bergin; Patrick D Schloss; Vincent B Young
Journal:  mBio       Date:  2021-03-30       Impact factor: 7.867

5.  Analysis of Perioperative Risk Factors for Clostridium difficile Infection After a Colectomy.

Authors:  Karen Kong; Sara S Soliman; Rolando H Rolandelli; Matthew J Elander; Joseph Flanagan; Daniel Hakakian; Zoltan H Nemeth
Journal:  Cureus       Date:  2021-12-03

Review 6.  Epidemiology of community-acquired and recurrent Clostridioides difficile infection.

Authors:  Yichun Fu; Yuying Luo; Ari M Grinspan
Journal:  Therap Adv Gastroenterol       Date:  2021-05-22       Impact factor: 4.409

7.  Systems biology evaluation of refractory Clostridioides difficile infection including multiple failures of fecal microbiota transplantation.

Authors:  Anne J Gonzales-Luna; Jennifer K Spinler; Numan Oezguen; Md Abdul Wadud Khan; Heather A Danhof; Bradley T Endres; M Jahangir Alam; Khurshida Begum; Chris Lancaster; Gabriela Pd Costa; Tor C Savidge; Julian G Hurdle; Robert Britton; Kevin W Garey
Journal:  Anaerobe       Date:  2021-05-24       Impact factor: 2.837

8.  Antimicrobial susceptibility and molecular characterisation using whole-genome sequencing of Clostridioides difficile collected in 82 hospitals in Japan between 2014 and 2016.

Authors:  Kotaro Aoki; Shinobu Takeda; Takashi Miki; Yoshikazu Ishii; Kazuhiro Tateda
Journal:  Antimicrob Agents Chemother       Date:  2019-09-16       Impact factor: 5.191

9.  Computational modeling of the gut microbiota reveals putative metabolic mechanisms of recurrent Clostridioides difficile infection.

Authors:  Michael A Henson
Journal:  PLoS Comput Biol       Date:  2021-02-22       Impact factor: 4.475

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.